Rocketing Biotech Stock Alert: Oragenics (NYSE: OGEN)

As a vaccine for treating COVID-19 patients is not ready yet to serve billions Oragenics (NYSE: OGEN) decides to join the rally by partnering with Avid Bioservices. Then, the penny stock starts to surge slowly in premarket by 15%.

On Thursday, OGEN gained 6.04% by nearly reaching $1.00 on the daily volume of 18,241,100 shares. Due to the cheap price, different traders may consider buying OGEN. Moreover, 12 months based EPS of -0.5230 isn’t as much bad as compared to other counterparts.

With the development of existing drug Terra CoV-2, Oragenics will proceed with clinical tests for improvement and after everything is done, Avid Bioservices is going to manufacture the prepared vaccine to neutralize SARS-COV-2.

Richard McEntire

Finance and Entertainment Reporter Richard is a bottle of wine - the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.